Comparison of efficacy and safety of combination of insulin glargine and lixisenatide + glulisine therapy and intensive insulin therapy in patients with type 2 diabetes - Comparison of efficacy and safety of combination of insulin glargine and lixisenatide + glulisine therapy and intensive insulin therapy in patients with type 2 diabetes

Minami Osaka Hospital0 个研究点目标入组 20 人开始时间: 2020年8月25日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients with severe gastrointestinal disorders such as severe gastroparesis. 2. Patients with a history of pancreatitis. 3. Patients with a history of severe ketosis, diabetic coma or pre-coma within 6 weeks of starting the study. 4.Patients with severe hypoglycemia (diabetic coma or precoma, convulsion that requires the assistance of a third party) within 6 weeks of starting the study. 5. Patients with severe renal dysfunction (eGFR less than 30mL/min/1.73m2 or serum creatinine level 2.0mg/dL or more) or patients with end-stage renal failure undergoing dialysis. 6. Patients with severe liver dysfunction (AST or ALT higher than 100U/L). 7. Patients with proliferative retinopathy (however, patients with stable symptoms who have undergone photocoagulation, etc. can be enrolled). 8. Pregnant or possibly pregnant women and lactating patients. 9. Patients with severe infections, serious injury before and after surgery. 10. Patients receiving systemic corticosteroids. 11. Patients with a history of allergies to the planned drug used in the study. 12. Patients with or history of malignancy. 13.Other patients who the investigator determined to be inappropriate as a subject.

发起方

Minami Osaka Hospital